patients interested in trial eligibility should speak to their GP or check ClinicalTrials.gov
Similar content being viewed by others Background Glucagon-like peptide-1 (GLP-1), incretin hormone, is secreted from epithelial cells in small intestine after meal ingestion and acts on the pancreas to promote insulin secretion
Ketogenic diet: a dietary intervention via gut microbiome modulation for the treatment of neurological and nutritional disorders (a narrative review)
Both are incretin-based therapies that affect appetite and insulin, and combining them could significantly increase your risk of side effects such as: Severe nausea or vomiting Pancreatitis Gastrointestinal distress Low blood sugar (especially if diabetic) In addition to the physical risks, combining these two would also confuse your treatment plan, making it harder to track which drug is delivering results or causing issues
So that can be a really long walk or hike
The expression level of GhGPX2 was induced in leaves by 24 h treatment with 400 mM NaCl, and the transcript levels of GhGPX1, 3, 5, 8, 13 decreased in leaves after treatment with 400 mM NaCl for 3 h (Fig
